治疗前血清白细胞介素-10水平升高预示食管癌总生存期较差
Elevated Pre-Treatment Serum Interleukin-10 Levels Predict Poor Overall Survival in Esophageal Cancer.
作者
作者单位
- Department of Thoracic and Cardiovascular Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC.
- Division of Pulmonology and Critical Care Medicine, Kaohsiung Municipal Ta-Tung Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC.
- Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC.
- Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ROC. lee.a0928@msa.hinet.net.
摘要
中文
我们旨在评估治疗前血清白细胞介素(IL)-10浓度是否可预测食管鳞状细胞癌患者的总生存期(OS)。这项单中心回顾性分析纳入了112例接受根治性同步放化疗的食管癌患者。收集治疗前血清样本,测量IL-10水平。患者被分为“低”和“高”IL-10两组。使用χ²或Fisher精确检验比较基线特征(年龄、饮酒、嚼槟榔、吸烟、临床T/N分期、国际癌症控制联盟[UICC]分期、肿瘤分级、原发部位和治疗)。使用Kaplan-Meier方法估计OS和无进展生存期,并使用log-rank检验进行比较。单变量分析中p<0.1的变量进入多变量Cox比例风险模型以确定独立预后因素。低和高IL-10组的基线人口统计学和临床病理特征相当。低IL-10组的1年和3年OS率分别为85%和50%,高IL-10组分别为56%和33%。单变量分析表明UICC分期和IL-10水平影响预后。晚期别和高IL-10表达是较短OS和无进展生存期的独立预测因子。Kaplan-Meier曲线显示,IL-10分层的生存率早期即出现差异,并随时间保持分离。治疗前血清IL-10水平高与食管鳞状细胞癌患者较差的生存相关,并且在调整临床分期后是独立的预后因素。作为一种微创生物标志物,血清IL-10有助于风险分层,并可能为免疫调节治疗策略提供信息。
English
Our objective was to evaluate whether pre-treatment serum interleukin (IL)-10 concentrations predicted overall survival (OS) in patients with esophageal squamous cell carcinoma. This single-center retrospective analysis included 112 patients with esophageal cancer who were treated with definitive concurrent chemoradiotherapy. Pre-treatment serum samples were collected, and IL-10 levels were measured. Patients were dichotomized into "low" and "high" IL-10 groups. Baseline characteristics (age, alcohol consumption, betel nut chewing, smoking, clinical T/N stage, Union for International Cancer Control [UICC] stage, tumor grade, primary location, and treatment) were compared using χ2 or Fisher's exact tests. OS and progression-free survival were estimated using the Kaplan-Meier method and compared using log-rank tests. Variables with p < 0.1 on univariable analysis were entered into a multivariable Cox proportional hazards model to identify independent prognostic factors. Baseline demographics and clinicopathological characteristics were comparable between the low- and high-IL-10 groups. The 1- and 3-year OS rates were 85% and 50% in the low-IL-10 group and 56% and 33% in the high-IL-10 group, respectively. Univariate analysis indicated that UICC stage and IL-10 level influenced prognosis. Advanced stage and high IL-10 expression were independent predictors of shorter OS and progression-free survival. Kaplan-Meier curves showed that survival diverged early between the IL-10 strata and remained separated over time. High pre-treatment serum IL-10 levels were associated with worse survival in patients with esophageal squamous cell carcinoma and constituted an independent prognostic factor after adjusting for clinical stage. As a minimally invasive biomarker, serum IL-10 can aid in risk stratification and may inform immunomodulatory treatment strategies.
分类与指标
- 研究类型
- 临床研究
- 病种
- 食管癌
- JCR 分区
- Q1
- 影响因子
- 3.8
- 新锐分区
- 2区